Avicanna Inc (AVCNF) fair value: what the stock is really worth
We calculate from audited financials what Avicanna Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Avicanna Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range $0.0750 – $1.02 · the $0.0860 price screens above the $0.0206 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally.
Show more
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, as well as Trunerox, an indication-specific drug treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Stock analysis
Avicanna Inc (AVCNF) currently trades at $0.0860, while our model-based Fair Value estimate is $0.0206, implying the stock looks roughly 316.7% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Avicanna Inc reported revenue of C$25.5M in FY2025 versus C$3.3M in FY2021, a compound +67.1%/yr. Reported net income was −C$2.8M in FY2025.
Key figures
Market cap $12.1M · P/S ratio 0.47 · EPS (TTM) $−0.0100 · Net margin −11.2% · Return on equity −26.5% · Return on assets (EBIT) −38.1% · Operating margin −4.6% · Revenue (TTM) $25.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (low confidence).
What moves the price
The share trades about 64% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at −76%, AVCNF screens richer than that median.
Fair Value models
Bear $0.0206Fair Value $0.0206Bull $0.0206
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+84.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+74.6%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+135.8%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,209.4% (2020) → −10.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 612 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−89% · Bottom 25%
Profitability
Return on assets−9% · Bottom 25%
Net margin (TTM)−12% · Bottom 25%
Operating margin (TTM)−5% · Bottom 25%
Growth and dividend
Revenue growth6% · Above median
Balance sheet
Debt / equity0.06× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Avicanna Inc Fair Value". https://www.fairvalue-calculator.com/stock/AVCNF
Frequently asked questions
Is Avicanna Inc (AVCNF) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.0206 versus a price of $0.0860, about −76% upside (overvalued).
What is the fair value of AVCNF?
Our model-based fair value for Avicanna Inc is $0.0206 (as of Sep 13, 2026), built from audited fundamentals. The current price: $0.0860.
What is the quality score of AVCNF?
Avicanna Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Avicanna Inc (AVCNF)?
Our model-based price target is the fair value of $0.0206 (as of Sep 13, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Avicanna Inc stock forecast for 2026?
Our models put fair value at $0.0206, about −76% upside versus a price of $0.0860 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Avicanna Inc (AVCNF)?
Avicanna Inc reported trailing-twelve-month revenue of about $25.8M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Avicanna Inc (AVCNF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Avicanna Inc it is $0.0206 per share (as of Sep 13, 2026), against a price of $0.0860. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Avicanna Inc stock overvalued or undervalued in 2026?
As of Sep 13, 2026, AVCNF trades above its calculated fair value: price $0.0860, fair value $0.0206, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AVCNF?
No. The price is what the market pays today ($0.0860); the fair value is what the company's own numbers justify ($0.0206). For Avicanna Inc the two are $0.0654 per share apart. That gap is exactly why we show both numbers side by side.
How much is Avicanna Inc worth?
The market values Avicanna Inc at about $12.1M (market capitalisation, as of Sep 13, 2026). Per share that is $0.0860; our models calculate a fair value of $0.0206 per share.
How solid is the balance sheet of Avicanna Inc (AVCNF)?
Balance-sheet figures for Avicanna Inc (as of Sep 13, 2026): return on equity −26.5%, debt of 0.06 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is AVCNF from its 52-week high?
Avicanna Inc trades at $0.0860, about 64% below its 52-week high of $0.2363 and 15% above the low of $0.0750 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0206 is for.
Which stocks are comparable to Avicanna Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Avicanna Inc stock attractive at the current price?
The data as of Sep 13, 2026: price $0.0860, calculated fair value $0.0206 (−76%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AVCNF calculated?
We run Avicanna Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0206, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Avicanna Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Avicanna Inc right now?
The price sits above even our optimistic bull case ($0.0206). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Avicanna Inc
How large is the market capitalisation of Avicanna Inc (AVCNF)?
The market capitalisation of Avicanna Inc is $12.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Avicanna Inc (AVCNF)?
The price-to-sales ratio of Avicanna Inc is 0.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Avicanna Inc (AVCNF)?
Earnings per share at Avicanna Inc are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Avicanna Inc (AVCNF)?
The net margin of Avicanna Inc is −11.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Avicanna Inc (AVCNF)?
The return on equity (ROE) of Avicanna Inc is −26.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Avicanna Inc (AVCNF)?
On an EBIT basis the return on assets of Avicanna Inc is −38.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Avicanna Inc (AVCNF)?
The operating margin of Avicanna Inc is −4.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Avicanna Inc (AVCNF)?
Revenue at Avicanna Inc is growing +5.6% versus a year earlier (3y avg +84.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Avicanna Inc (AVCNF) generate?
The free cash flow of Avicanna Inc is −$1.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Avicanna Inc (AVCNF) carry?
The net debt of Avicanna Inc is $1.1M (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Avicanna Inc in the live analysis
One click puts Avicanna Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 13, 2026